Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
PrECOG, LLC.
AstraZeneca
Pfizer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sheba Medical Center
Istituto Oncologico Veneto IRCCS
Boehringer Ingelheim
First Affiliated Hospital of Zhejiang University
Shanghai JMT-Bio Inc.
Fundación GECP
Boehringer Ingelheim
Guangdong Association of Clinical Trials
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Sungkyunkwan University
AstraZeneca